Stock listing
Frankfurt:7JK EQL Pharma AB Aktie
German listing (Frankfurt) of EQL Pharma AB · home listing Stockholm:EQL
Follow EQL Pharma AB into a list and get an email when it puts out news.
Share price · FWB:7JK
€1.92 EUR -0.01 (-0.6%)
Close on Nov 20, 2026
- Day range
- €1.90 – €1.92 EURNov 20, 2026
- Market cap
- €56.76M EURAt the close on Nov 20, 2026 · price × 29.53M shares outstanding
- 52-week range
- €1.65 – €6.21 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:EQL · Home | 21.65 SEK | -0.60 (-2.7%) | 26,451 | 22.90 | 22.90 | 21.20 | 22.25 | Close on Nov 20, 2026 |
| Frankfurt:7JK | €1.922 EUR | -0.012 (-0.6%) | — | €1.90 | €1.922 | €1.90 | €1.934 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:7JK · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €2.254 | -0.048 | -2.1% | €2.191 | €2.285 | €2.176 | 0 | |
| €2.302 | +0.287 | +14.2% | €2.307 | €2.416 | €2.281 | 0 | |
| €2.015 | +0.204 | +11.3% | €1.852 | €2.043 | €1.845 | 0 | |
| €1.811 | +0.003 | +0.2% | €1.832 | €1.832 | €1.811 | 0 | |
| €1.808 | +0.082 | +4.8% | €1.758 | €1.816 | €1.748 | 0 | |
| €1.726 | +0.046 | +2.7% | €1.683 | €1.726 | €1.667 | 0 | |
| €1.68 | -0.002 | -0.1% | €1.688 | €1.69 | €1.676 | 0 | |
| €1.682 | +0.013 | +0.8% | €1.693 | €1.694 | €1.672 | 0 | |
| €1.669 | -0.043 | -2.5% | €1.677 | €1.677 | €1.65 | 0 | |
| €1.712 | -0.007 | -0.4% | €1.741 | €1.75 | €1.707 | 0 | |
| €1.719 | -0.023 | -1.3% | €1.731 | €1.736 | €1.718 | 0 | |
| €1.742 | +0.001 | +0.1% | €1.749 | €1.749 | €1.732 | 0 | |
| €1.741 | -0.015 | -0.9% | €1.736 | €1.75 | €1.716 | 0 | |
| €1.756 | -0.093 | -5.0% | €1.815 | €1.856 | €1.737 | 0 | |
| €1.849 | -0.067 | -3.5% | €1.90 | €1.923 | €1.839 | 0 | |
| €1.916 | -0.024 | -1.2% | €1.903 | €1.919 | €1.90 | 0 | |
| €1.94 | -0.005 | -0.3% | €1.928 | €1.946 | €1.912 | 0 | |
| €1.945 | +0.003 | +0.2% | €1.954 | €1.966 | €1.942 | 0 | |
| €1.942 | +0.002 | +0.1% | €1.901 | €1.962 | €1.898 | 0 | |
| €1.94 | +0.008 | +0.4% | €1.826 | €1.97 | €1.815 | 0 | |
| €1.932 | +0.054 | +2.9% | €1.892 | €1.947 | €1.876 | 0 | |
| €1.878 | -0.145 | -7.2% | €2.058 | €2.058 | €1.873 | 0 | |
| €2.023 | -0.01 | -0.5% | €2.022 | €2.033 | €2.017 | 0 | |
| €2.033 | +0.059 | +3.0% | €2.017 | €2.05 | €1.999 | 0 | |
| €1.974 | -0.184 | -8.5% | €1.938 | €1.978 | €1.931 | 0 | |
| €2.158 | +0.205 | +10.5% | €1.99 | €2.207 | €1.989 | 0 | |
| €1.953 | -0.021 | -1.1% | €1.955 | €1.968 | €1.953 | 0 | |
| €1.974 | -0.01 | -0.5% | €1.966 | €1.986 | €1.955 | 0 | |
| €1.984 | +0.004 | +0.2% | €1.976 | €1.986 | €1.967 | 0 | |
| €1.98 | +0.003 | +0.2% | €2.007 | €2.012 | €1.969 | 0 | |
| €1.977 | -0.003 | -0.2% | €1.98 | €2.013 | €1.977 | 0 | |
| €1.98 | -0.03 | -1.5% | €1.984 | €1.985 | €1.979 | 0 | |
| €2.01 | +0.003 | +0.1% | €2.01 | €2.01 | €1.996 | 0 | |
| €2.007 | -0.037 | -1.8% | €2.012 | €2.012 | €1.998 | 0 | |
| €2.044 | -0.125 | -5.8% | €2.13 | €2.143 | €2.027 | 0 | |
| €2.169 | +0.013 | +0.6% | €2.155 | €2.17 | €2.123 | 0 | |
| €2.156 | -0.005 | -0.2% | €2.158 | €2.158 | €2.145 | 0 | |
| €2.161 | -0.09 | -4.0% | €2.24 | €2.245 | €2.155 | 0 | |
| €2.251 | -0.002 | -0.1% | €2.25 | €2.251 | €2.244 | 0 | |
| €2.253 | -0.023 | -1.0% | €2.258 | €2.271 | €2.233 | 0 | |
| €2.276 | -0.036 | -1.6% | €2.292 | €2.31 | €2.274 | 0 | |
| €2.312 | -0.041 | -1.7% | €2.325 | €2.325 | €2.309 | 0 | |
| €2.353 | -0.066 | -2.7% | €2.406 | €2.418 | €2.351 | 0 | |
| €2.419 | +0.047 | +2.0% | €2.426 | €2.427 | €2.382 | 0 | |
| €2.372 | +0.103 | +4.5% | €2.302 | €2.373 | €2.298 | 0 | |
| €2.269 | +0.019 | +0.8% | €2.277 | €2.30 | €2.246 | 0 | |
| €2.25 | +0.052 | +2.4% | €2.197 | €2.254 | €2.192 | 0 | |
| €2.198 | -0.098 | -4.3% | €2.252 | €2.266 | €2.188 | 0 | |
| €2.296 | -0.024 | -1.0% | €2.314 | €2.321 | €2.286 | 0 | |
| €2.32 | +0.073 | +3.2% | €2.261 | €2.324 | €2.254 | 0 | |
| €2.247 | -0.119 | -5.0% | €2.231 | €2.25 | €2.186 | 0 | |
| €2.366 | -0.091 | -3.7% | €2.444 | €2.451 | €2.362 | 0 | |
| €2.457 | +0.087 | +3.7% | €2.394 | €2.467 | €2.385 | 0 | |
| €2.37 | +0.008 | +0.3% | €2.375 | €2.381 | €2.363 | 0 | |
| €2.362 | +0.062 | +2.7% | €2.347 | €2.364 | €2.328 | 0 | |
| €2.30 | -0.007 | -0.3% | €2.239 | €2.313 | €2.222 | 0 | |
| €2.307 | -0.011 | -0.5% | €2.364 | €2.384 | €2.285 | 0 |
- Ticker
- Frankfurt:7JK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Jul 27, 2026
EQL Pharma recruits Oskar Karmlid as new Chief Supply Chain Officer (CSCO)
Latest deck · Nov 5, 2026
Q2 2026/27 Earnings Presentation
Earnings · 12 slides
Latest news
EQL Pharma recruits Oskar Karmlid as new Chief Supply Chain Officer (CSCO)
Jul 27, 2026
Closed €1.83 (+3.6%) on Jul 27, 2026
EQL Pharma AB on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 1 in the last 12 months · 2 in all · newest Jul 27, 2026 · oldest 2025
- Calls
- 6 calls with a replay · 6 with a transcript · latest Sep 12, 2023
- Decks
- 4 decks · latest Nov 5, 2026
Where EQL Pharma AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:EQL · Home listing | Stockholm | Sweden | SEK |
| gettex:7JK | gettex | Germany | EUR |
| LS Exchange:A12AZY | LS Exchange | Germany | EUR |
| Turquoise:EQLS | Turquoise | United Kingdom | SEK |
| Lang & Schwarz:A12AZY | Lang & Schwarz | Germany | EUR |
| Stuttgart:7JK | Stuttgart | Germany | EUR |
| Dusseldorf:7JK | Dusseldorf | Germany | EUR |
| Frankfurt:7JK · This page | Frankfurt | Germany | EUR |
| Munich:7JK | Munich | Germany | EUR |
Valuation
P/E 51.0× against a median of 8.7×: the highest of 8 Pharmaceuticals companies shown. Statements: Year to Mar 31, 2026 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 578.2M SEK
- P/E
- 51.0×
- EV/sales
- 1.3×
- EV/EBITDA
- 8.1×
- Price/book
- 2.5×
- Gross margin
- 37.6%
- Operating margin
- 11.3%
- Net margin
- 2.9%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| EQL Pharma AB · OMXSTO:EQL | US$62.53M | US$56.55M | 51.0× | 1.3× | 8.1× | 2.5× | 2.9% | 0.0× | n/a |
| Wanbury Limited · NSE:WANBURY | US$67.68M | US$67.68M | 11.2× | 1.0× | 6.4× | 4.3× | 8.6% | 0.0× | n/a |
| Euroapi SA · EURONEXT:EAPI | US$67.31M | US$343.1M | n/a | 0.4× | 31.6× | 0.1× | −24.9% | 0.5× | n/a |
| Bangkok Lab and Cosmetic Public Company Limited · SET:BLC | US$66.78M | US$65.27M | 16.6× | 1.4× | 9.0× | 1.4× | 8.4% | 0.0× | n/a |
| JW Shinyak Corp. · KRX:067290 | US$66.62M | US$63.79M | 8.7× | 1.0× | 6.9× | 2.2× | 12.1% | 0.0× | n/a |
| Laboratorios Richmond SACIF Class B · BCBA:RICH | US$65.34M | US$173.1M | 8.4× | 2.1× | 7.5× | 0.9× | 9.3% | 1.5× | n/a |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A · TWSE:1762 | US$63.36M | US$76.28M | n/a | 2.7× | 51.1× | 0.7× | −5.5% | 0.2× | n/a |
| Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H · HKEX:8049 | US$63.16M | −US$71.93M | 1.5× | −0.4× | −1.4× | 0.2× | 25.1% | 0.0× | n/a |
| Choong Ang Vaccine Laboratory · KRX:072020 | US$61.86M | US$44.61M | 10.4× | 1.2× | 4.4× | 0.8× | 16.6% | 0.0× | n/a |
| Korea Pharma Co., Ltd. · KRX:032300 | US$59.92M | US$47.49M | n/a | 0.7× | 13.4× | 1.1× | −0.8% | 0.2× | n/a |
| High Tech Pharm. Co., Ltd. · KRX:106190 | US$59.61M | US$57.37M | 6.7× | 1.1× | 4.3× | 0.6× | 17.2% | 0.0× | n/a |
| Median of the others | US$64.35M | US$64.53M | 8.7× | 1.1× | 7.2× | 0.8× | 8.9% | 0.0× |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 45.00 SEK · Analysts' mean
- EPS, year to Mar 2027
- 1.48 · 1 analyst
- Revenue, year to Mar 2027
- 499M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Axel Schörling | President and CEO |
| Allan Sylvest Aasberg | CFO |
| Martin Kristofferson | COO |
| Anne Drew Jensen | Chief Sales Officer |
| Cornelia Lindström | Chief Regulatory Officer |
| Ivana Antolaš | Chief Quality Officer |
| Oskar Karmlid | Chief Supply Chain Officer |
Board
| Director | Role |
|---|---|
| Christer Fåhraeus | Chairman of the Board |
| Anders Månsson | Board member |
| Linda Neckmar | Board member |
| Niraj Kumar | Board member |
| Per Svangren | Board member |
| Raymond de Vre | Board member |
Events
Calls
| Call | When | Status |
|---|---|---|
| EQL Pharma (Stockholm:EQL) — Interim Results | Tue, Sep 12, 2023 · 1:00 PM ET | Replay |
| EQL Pharma (Stockholm:EQL) — Full Year Results | Mon, Mar 27, 2023 · 1:00 PM ET | Replay |
| EQL Pharma (Stockholm:EQL) — Interim Results | Wed, Sep 07, 2022 · 1:00 PM ET | Replay |
| EQL Pharma (Stockholm:EQL) — FY-2021 Results & Q1-2022 Trading Update’ | Wed, Mar 30, 2022 · 1:00 PM ET | Replay |
| EQL Pharma (Stockholm:EQL) — Interim Results | Fri, Sep 17, 2021 · 6:00 AM ET | Replay |
| EQL Pharma (Stockholm:EQL) — Final results for the year ended 31 December 2020 | Thu, Apr 22, 2021 · 10:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 5, 2026 · Before open | +14.3% |
| Q1 2027 | Aug 7, 2026 · Before open | −7.8% |
| Q4 2026 | May 8, 2026 · Before open | −42.4% |
| Q3 2026 | Feb 3, 2026 · Before open | −6.7% |
| Q2 2026 | Nov 5, 2025 · Before open | −10.3% |
| Q1 2026 | Aug 8, 2025 · Before open | −4.6% |
| Q4 2025 | May 8, 2025 · Before open | +7.7% |
| Q3 2025 | Feb 5, 2025 · Before open | +3.3% |
| Q2 2025 | Nov 6, 2024 · Before open | +3.0% |
| Q1 2025 | Aug 8, 2024 · Before open | +7.2% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | May 14, 2024 · After close | |
| Q3 2024 | Feb 13, 2024 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026/27 Earnings Presentation | Earnings | 12 slides | Nov 5, 2026 |
| Q1 2026/27 Earnings Presentation | Earnings | 11 slides | 2026 |
| Investor Day (March 2025) | Investor day | 45 slides | Mar 7, 2025 |
| Investor Presentation (January 2025) | Investor deck | 45 slides | January 2025 |
Financials
Annual, in SEK
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 432.7M | 373.5M | 264.2M | 259.9M | 409.8M | 179.1M |
| Cost of revenue | 269.8M | 217.6M | 149.1M | 144.1M | 314.0M | 128.1M |
| Gross profit | 162.8M | 156.0M | 115.0M | 115.8M | 95.7M | 51.0M |
| Research and development | 14.3M | 11.3M | 12.1M | 15.1M | 9.13M | 11.7M |
| Selling, general and administrative | 102.9M | 78.5M | 70.8M | 59.8M | 48.2M | 28.3M |
| Operating income | 48.7M | 67.4M | 32.6M | 41.1M | 38.6M | 11.2M |
| Depreciation and amortization | 23.1M | 12.5M | 8.75M | 14.2M | 10.3M | 17.3M |
| EBITDA | 71.8M | 79.9M | 41.4M | 55.3M | 48.8M | 28.5M |
| Interest expense | 30.5M | 13.0M | 5.73M | 2.37M | 2.87M | 1.10M |
| Income before tax | 18.2M | 54.4M | 28.6M | 39.0M | 36.0M | 10.4M |
| Income tax | 5.67M | 11.2M | 5.90M | |||
| Net income | 12.5M | 43.1M | 22.7M | 30.9M | 31.5M | 10.4M |
| Earnings per share, basic | 0.42 | 1.48 | 0.78 | 1.06 | 1.09 | 0.36 |
| Earnings per share, diluted | 0.42 | 1.44 | 0.76 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 86.8M | 82.4M | 20.5M | 44.4M | 41.2M | 26.6M |
| Receivables | 92.7M | 125.7M | 58.3M | 51.7M | 34.1M | 21.8M |
| Inventory | 200.5M | 179.0M | 105.6M | 65.4M | 41.7M | 42.4M |
| Current assets | 403.9M | 400.3M | 197.8M | 167.2M | 123.5M | 97.8M |
| Property, plant and equipment | 5.90M | 6.32M | 2.67M | |||
| Total assets | 850.9M | 808.8M | 373.8M | 285.7M | 237.9M | 203.5M |
| Accounts payable | 70.3M | 90.9M | 49.8M | 29.6M | 16.0M | 19.0M |
| Current liabilities | 210.2M | 221.0M | 162.1M | 117.2M | 98.8M | 94.9M |
| Long-term debt | 345.2M | 341.8M | 15.5M | 0 | 7.20M | 12.6M |
| Total liabilities | 583.8M | 587.8M | 196.0M | 130.9M | 114.3M | 112.3M |
| Shareholders' equity | 267.1M | 221.0M | 177.7M | 154.8M | 123.6M | 91.2M |
| Shares outstanding | 29.5M | 29.1M | 29.1M | 29.1M | 29.1M | 29.1M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Cash from operations | 28.4M | -24.7M | -11.4M | 27.6M | 41.8M | 60.0M |
| Capital spending | -5.44M | -6.13M | -926.0K | -20.5M | -22.1M | -55.6M |
| Free cash flow | 22.9M | -30.8M | -12.4M | 7.11M | 19.7M | 4.47M |
| Cash from investing | -67.2M | -245.8M | -66.3M | |||
| Cash from financing | 43.2M | 332.4M | 53.7M | |||
| Change in cash | 4.36M | 61.9M | -24.0M | 3.23M | 14.6M | 16.3M |
Cap table
Built by 6ix from EQL Pharma AB’s releases
- Common shares
- 29,529,610
- Fully diluted
- 29,529,610
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 29,529,610 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 29,529,610 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Allan Sylvest Aasberg | CFO · Since at least Nov 5, 2026 |
| Anders Månsson | Board member · Since at least Nov 5, 2026 |
| Anne Drew Jensen | Chief Sales Officer · Since at least Nov 5, 2026 |
| Axel Schörling | President and CEO · Since at least Jul 27, 2026 |
| Christer Fåhraeus | Chairman of the Board · Since at least Nov 5, 2026 |
| Cornelia Lindström | Chief Regulatory Officer · Since at least Nov 5, 2026 |
| Ivana Antolaš | Chief Quality Officer · Since at least Nov 5, 2026 |
| Linda Neckmar | Board member · Since at least Nov 5, 2026 |
| Martin Kristofferson | COO · Since at least Jul 27, 2026 |
| Niraj Kumar | Board member · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Oskar Karmlid | Chief Supply Chain Officer · Since at least Jul 27, 2026 |
| Per Svangren | Board member · Since at least Nov 5, 2026 |
| Raymond de Vre | Board member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about EQL Pharma AB.